Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly - PubMed (original) (raw)
Review
. 2002 Feb 22;90(3):251-62.
Affiliations
- PMID: 11861412
Review
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly
Zorina S Galis et al. Circ Res. 2002.
Abstract
Vascular remodeling, defined as any enduring change in the size and/or composition of an adult blood vessel, allows adaptation and repair. On the other hand, inappropriate remodeling, including its absence, underlies the pathogenesis of major cardiovascular diseases, such as atherosclerosis and restenosis. Since degradation of the extracellular matrix scaffold enables reshaping of tissue, participation of specialized enzymes called matrix metalloproteinases (MMPs) has become the object of intense recent interest in relation to physiological ("good") and pathological ("bad") vascular remodeling. Experimental evidence acquired in vitro and in vivo suggests that the major drivers of vascular remodeling, hemodynamics, injury, inflammation, and oxidative stress, regulate MMP expression and activity. Alternatively, nonspecific MMP inhibition seems to oppose remodeling, as suggested by the inhibition of intimal thickening and outward arterial remodeling. An emerging concept is that MMP-related genetic variations may contribute to heterogeneity in the presentation and natural history of atherosclerosis. The hypothesis that MMPs contribute to weakening of atherosclerotic plaques is especially attractive for the potential development of therapeutic interventions aimed at preventing plaque disruption ("the ugly"), a major cause of acute cardiovascular events. However, the current lack of appropriate experimental tools, including availability of specific MMP inhibitors and pertinent animal models, still limits our understanding of the many actions and relative contributions of specific MMPs. Our future potential ability to control vascular remodeling via regulation of MMPs will also depend on reaching a consensus of what is indeed "good" or "bad" vascular remodeling, concepts that have continued to evolve and change.
Similar articles
- Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.
Newby AC. Newby AC. Physiol Rev. 2005 Jan;85(1):1-31. doi: 10.1152/physrev.00048.2003. Physiol Rev. 2005. PMID: 15618476 Review. - Vascular remodeling and protease inhibition--bench to bedside.
Sluijter JP, de Kleijn DP, Pasterkamp G. Sluijter JP, et al. Cardiovasc Res. 2006 Feb 15;69(3):595-603. doi: 10.1016/j.cardiores.2005.11.026. Epub 2006 Jan 4. Cardiovasc Res. 2006. PMID: 16387286 Review. - What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
Janssens S, Lijnen HR. Janssens S, et al. Cardiovasc Res. 2006 Feb 15;69(3):585-94. doi: 10.1016/j.cardiores.2005.12.010. Epub 2006 Jan 19. Cardiovasc Res. 2006. PMID: 16426591 Review. - Plasmin and matrix metalloproteinases in vascular remodeling.
Lijnen HR. Lijnen HR. Thromb Haemost. 2001 Jul;86(1):324-33. Thromb Haemost. 2001. PMID: 11487021 Review. - Molecular mechanism for activation and regulation of matrix metalloproteinases during bacterial infections and respiratory inflammation.
Okamoto T, Akuta T, Tamura F, van Der Vliet A, Akaike T. Okamoto T, et al. Biol Chem. 2004 Nov;385(11):997-1006. doi: 10.1515/BC.2004.130. Biol Chem. 2004. PMID: 15576319 Review.
Cited by
- Lipotoxicity-Related Hematological Disorders in Obesity.
Haznedaroglu IC, Malkan UY. Haznedaroglu IC, et al. Adv Exp Med Biol. 2024;1460:575-594. doi: 10.1007/978-3-031-63657-8_19. Adv Exp Med Biol. 2024. PMID: 39287865 Review. - Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer.
Todorova VK, Azhar G, Stone A, Malapati SJ, Che Y, Zhang W, Makhoul I, Wei JY. Todorova VK, et al. Int J Mol Sci. 2024 Sep 9;25(17):9735. doi: 10.3390/ijms25179735. Int J Mol Sci. 2024. PMID: 39273682 Free PMC article. - Matrix Metalloproteinase-2 and CKD Progression: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Baudier RL, Orlandi PF, Yang W, Chen HY, Bansal N, Blackston JW, Chen J, Deo R, Dobre M, He H, He J, Ricardo AC, Shafi T, Srivastava A, Xie D, Susztak K, Feldman HI, Anderson AH; CRIC Study Investigators. Baudier RL, et al. Kidney Med. 2024 Jun 6;6(8):100850. doi: 10.1016/j.xkme.2024.100850. eCollection 2024 Aug. Kidney Med. 2024. PMID: 39131916 Free PMC article. - Oral Nanoformulations in Cardiovascular Medicine: Advances in Atherosclerosis Treatment.
Sun X, Jia X, Tan Z, Fan D, Chen M, Cui N, Liu A, Liu D. Sun X, et al. Pharmaceuticals (Basel). 2024 Jul 10;17(7):919. doi: 10.3390/ph17070919. Pharmaceuticals (Basel). 2024. PMID: 39065770 Free PMC article. Review. - Early Growth Response Protein 1 Exacerbates Murine Inflammatory Bowel Disease by Transcriptional Activation of Matrix Metalloproteinase 12.
Chen SY, Fang CY, Su BH, Chen HM, Huang SC, Wu PT, Shiau AL, Wu CL. Chen SY, et al. Biomedicines. 2024 Apr 2;12(4):780. doi: 10.3390/biomedicines12040780. Biomedicines. 2024. PMID: 38672136 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials